- Oops!Something went wrong.Please try again later.
BEVERLY, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army’s Combat Capabilities Development Command (DEVCOM) (https://www.cbc.devcom.army.mil/).
This CRADA aims to foster innovative biothreat defense capability development, which is part of DEVCOM’s current technology priorities. LexaGene will work with the United States Army to demonstrate the capabilities of the MiQLabTM, LexaGene’s flagship pathogen detection system.
Dr. Manoj Nair, Director Applications & Assay Development at LexaGene comments, "This CRADA enables our team to work with biothreat specialists within DEVCOM who have access to unique biothreat samples and secure government laboratory facilities. This working arrangement is critical for us to advance our goal of providing technology for biothreat detection to the United States government."
Under this agreement, LexaGene will deliver a MiQLab system to DEVCOM for the purpose of determining the system’s ability to detect Bacillus anthracis and Yersinia pestis, which cause anthrax and plague, respectively. DEVCOM will determine the system’s sensitivity (e.g., limit-of-detection) for these two pathogens as well as evaluate the system’s quantitative detection capability.
Dr. Jack Regan, LexaGene’s CEO and Founder states, “Early in my career, I helped develop the Autonomous Pathogen Detection System (APDS), which was selected by the U.S. Department of Homeland Security to be the first autonomous detector component of their BioWatch antiterrorism program (https://pubmed.ncbi.nlm.nih.gov/18763806/). Through this work, I was inspired to improve the APDS technology, so I invented the technology that LexaGene is now commercializing. LexaGene’s MiQLab is open-access, making it much more nimble for quickly responding to a novel threat. I am very pleased to be working again with the U.S. government and look forward to demonstrating to the Army the benefits of the MiQLab’s open-access technology for the rapid detection of bio-threat agents.”
This work will be conducted at both LexaGene and DEVCOM Chemical Biological Center at Aberdeen Proving Grounds, MD.
On Behalf of the Board of Directors
Dr. Jack Regan
Chief Executive Officer & Chairman
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
About U.S. Army Combat Capabilities Development Command
The U.S. Army Combat Capabilities Development Command, known as DEVCOM, is the Army's technology leader and largest technology developer. DEVCOM ensures the dominance of Army capabilities by creating, integrating and delivering technology-enabled solutions to our Soldiers.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Corporate Contact: Gail Winslow Director of Marketing firstname.lastname@example.org 978.482.6237 email@example.com 800.215.1824 Media: Katie Gallagher Assistant Vice President, PR and Media Relations LavoieHealthScience firstname.lastname@example.org 617.792.3937 Investors: Sharon Choe Vice President LaVoieHealthScience email@example.com 857.241.7393